Skip to Main Content

Thanks to its response to the Covid-19 pandemic, the pharmaceutical industry has greatly improved its controversial image among patient advocacy groups, according to a new survey.

Specifically, 59% of patient groups thought brand-name drugmakers developed an “excellent” or “good” reputation last year, up from 50% in 2020. This was also the best showing since the survey was started in 2011 by PatientView, a research firm that canvassed 2,150 patient groups from 89 countries between November 2021 and February 2022. The firm rated the reputations of 47 companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment